SCHEDULE: Pivotal BioVenture Exits Inozyme Pharma Stake

Pivotal bioVenture Partners and its affiliates have ceased to be beneficial owners of Inozyme Pharma, Inc. after tendering over 4.49 million shares in a BioMarin Pharmaceutical tender offer.

Summary

• Pivotal bioVenture Partners Fund I, L.P., Pivotal bioVenture Partners Fund II, L.P., and their affiliated entities (collectively, "Reporting Persons") have ceased to be beneficial owners of more than five percent of Inozyme Pharma, Inc.'s Common Stock.
• The Reporting Persons tendered an aggregate of 4,494,851 shares of Common Stock in a tender offer.
• The shares were accepted by BioMarin Pharmaceutical Inc. at a price of $4.00 per share.
• The tender offer was accepted one minute past 11:59 p.m. Eastern Time on June 30, 2025.
• Following the settlement of the Tender Offer, on July 1, 2025, the Reporting Persons' beneficial ownership in Inozyme Pharma, Inc. became 0.00 shares, representing 0% of the class.

Sentiment

Score: 7

Explanation: The filing indicates a successful and complete exit for a significant investor group via a tender offer, which is generally a positive outcome for the selling entity, realizing a specific value for their investment. While it doesn't speak to Inozyme Pharma's operational performance, it reflects a completed transaction at a defined price.

Positives

• Reporting Persons successfully divested their entire stake of 4,494,851 shares in Inozyme Pharma, Inc. through a tender offer.
• The shares were sold at a price of $4.00 per share, providing a clear exit valuation for the investment.

Negatives

• No explicit negatives are stated from the perspective of the reporting persons, as the tender offer was a voluntary transaction.
• For Inozyme Pharma, the exit of a significant institutional investor could be perceived as a loss of a long-term holder, though the context of BioMarin's tender offer might imply a larger strategic move.

Future Outlook

The filing does not provide any forward-looking statements or guidance regarding Inozyme Pharma, Inc.'s future operations or financial performance. It solely reports a past transaction related to beneficial ownership.

Industry Context

The divestment of a significant stake by a venture capital firm like Pivotal bioVenture Partners in a biotechnology company often occurs following a strategic event, such as a tender offer by another pharmaceutical company (BioMarin Pharmaceutical Inc. in this case). This could indicate a successful exit for the venture capital firm, potentially realizing gains on their investment, or it could be part of a larger consolidation or acquisition strategy within the biotech sector involving Inozyme Pharma.

Comparison to Industry Standards

• NA. This filing details a specific transaction by a particular investor group and does not provide data for direct comparison to industry benchmarks or competitor performance. The tender offer price of $4.00 per share would need to be evaluated against Inozyme Pharma's historical stock performance and valuation metrics relative to its peers at the time of the offer to assess its attractiveness.

Stakeholder Impact

• Reporting Persons (Pivotal bioVenture Partners and affiliates): Successfully exited their investment in Inozyme Pharma, Inc., realizing proceeds of approximately $17.98 million.
• Inozyme Pharma, Inc. Shareholders: The exit of a major institutional investor could lead to a shift in the shareholder base and potentially influence trading dynamics, depending on the broader context of BioMarin's tender offer.
• BioMarin Pharmaceutical Inc.: The acquirer in the tender offer, indicating a strategic interest in Inozyme Pharma, Inc. or its assets.

Key Dates

Keywords

Inozyme Pharma, Pivotal bioVenture Partners, BioMarin Pharmaceutical, Tender Offer, Beneficial Ownership, Schedule 13D, Biotechnology, Pharmaceuticals, Investment Exit, Common Stock